Drug Information

Drug General Information
Drug ID
D0O2XJ
Former ID
DIB013496
Drug Name
NXN-188
Synonyms
Acute migraine therapy, NeurAxon; NXN-188 (oral); NXN-188 (oral), NeurAxon
Drug Type
Small molecular drug
Indication Migraine [ICD9: 346; ICD10:G43] Phase 2 [522692]
Company
Neuraxon
Formula
C27H36N8O5
PubChem Compound ID
123853
Target and Pathway
Target(s) 5-hydroxytryptamine 1B receptor Target Info Modulator
5-hydroxytryptamine 1D receptor Target Info Modulator
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Serotonergic synapsehsa04024:cAMP signaling pathway
Serotonergic synapse
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
5HT1 type receptor mediated signaling pathway
Reactome Serotonin receptors
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
G alpha (i) signalling events
WikiPathways Serotonin HTR1 Group and FOS Pathway
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway
GPCR downstream signaling
References
Ref 522692ClinicalTrials.gov (NCT00920686) Study of NXN 188 for the Treatment of Migraine With Aura. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.